The efficacy and safety in canaglifrozin therapy for diabetes complicated by non-alcoholic fatty liver disease.
Not Applicable
- Conditions
- onalcoholic fatty liver disease type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000023044
- Lead Sponsor
- Kyoto prefetural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
administration of SGLT2 inhibitors type 1 diabetes platelet count<100000/microL eGFR<45m/min/1.73m2 diagnosed heart failure or malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum level of ALT at baseline and end of 12 weeks. The change of ALT between baseline and end of 12 weeks administration.
- Secondary Outcome Measures
Name Time Method serum level of AST, GGT, ALP, HbA1c, fasting glucose, fasting insulin, c peptide, platelet count, uric acid, total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, hyaluronic acid, type 4 collagen 7s. waist circumference, NAFIC score, FIB-4 index, FM-fibro index, body composition, LSM, CAP, DEBQ, SF-8TM